Mammoth Biosciences, Inc. Overview
Pro stress-test →Mammoth Biosciences is a San Francisco-based biotechnology company co-founded by Nobel laureate Jennifer Doudna that develops novel CRISPR-based platforms for both in vivo gene editing therapeutics and molecular diagnostics. The company has leveraged ultra-compact CRISPR systems (NanoCas, CasPhi) and its proprietary DETECTR platform to enable flexible delivery mechanisms and diverse editing modalities for disease detection and treatment across healthcare, agriculture, and biodefense applications.
Strategic Profile
Pro stress-test →Mammoth is transitioning from a diagnostics-focused company toward therapeutic CRISPR applications, targeting permanent genetic cures through partnerships with major pharmaceutical firms like Regeneron (partnership announced April 2024). With lead drug candidate MB-111 designated in May 2025, the company aims to establish itself as a foundational platform provider in the genomics era, leveraging its strong IP from Doudna and early-stage partnerships with leading biotech and pharma companies.
Competitive Landscape
Pro stress-test →Mammoth faces a crowded CRISPR landscape dominated by Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, and Metagenomi Therapeutics, as well as emerging players in ultracompact CRISPR systems. Its differentiation rests on ultra-compact enzyme engineering, dual therapeutics-diagnostics portfolio, and partnerships with major pharma (Regeneron) and research institutions. The company competes on both technology IP and speed-to-clinic for in vivo gene editing applications.
Industry Context
Mammoth Biosciences, Inc. operates in Gene editing therapeutics.
Key facts
Founded: 2017 · Headquarters: San Francisco, US · Employees: 164 · Revenue: N/A · Market cap: N/A